Search Results for: THERAPEUTIC FOCUS A New Patented
Articles
THERAPEUTIC FOCUS - A New Patented Device for Treating Obstructive Sleep Apnea & Snoring May 30, 2017
Bob Wieden presents a device he believes addresses the underlying anatomic and physiologic etiology of snoring and OSA in a simple but inventive way, and if developed, has the ability to increase patient compliance by reducing the use of CPAP machines, by making a sufferer’s life more comfortable, while preventing many of the contributing diseases.
Biognosys Expands US Footprint With New Proteomics CRO Facility in Massachusetts January 23, 2024
Biognosys recently announced the operational readiness of its new proteomics facility in Massachusetts. This US expansion facilitates access to select proteomics contract research organization (CRO) services for our US biopharma customers…..
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint0Resistant Metastatic Melanoma Phase 1 Trial December 8, 2023
TILT Biotherapeutics recently presented safety and efficacy data from its international Phase 1 trial in patients with metastatic melanoma (NTC04217473),...Lubrizol Licenses Award-Winning Apisolex™ Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic June 21, 2023
The Lubrizol Corporation recently announced the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton). The license allows….
Sania Therapeutics Launches to Advance Novel Medicines for Neural Circuit Dysfunction May 17, 2023
Sania Therapeutics, focused on developing genetic medicines for neural circuit dysfunction, recently launched by unveiling its suite of proprietary patented platforms at….
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib & Stenoparib Combination in Advanced Solid Tumors March 20, 2023
Allarity Therapeutics, Inc. recently announced it has dosed the first patient in a Phase 1b clinical study evaluating the combination...Celltrion & Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment January 9, 2023
Rani Therapeutics Holdings, Inc. recently announced it has partnered with Celltrion for the development of RT-111, an orally administered ustekinumab biosimilar….
SOLUBILITY ENHANCEMENT - How Microparticles are Opening Doors to New Solutions for Oral Drug Delivery August 31, 2022
Jessica Mueller-Albers, PhD, Yiming Ma, PhD, Alexander Bernhardt, PhD, and Michael Damm review the use of microparticles for solubility enhancement of oral small molecules and how this approach can address the challenges in pharmaceutical formulations.
TFF Pharmaceuticals Expands R&D Operations With New Austin Facility July 14, 2022
TFF Pharmaceuticals, Inc. recently announced a significant expansion of its R&D operations through the lease of a new research and...Biogen & MedRhythms to Develop & Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis May 5, 2022
Biogen Inc. and MedRhythms have recently entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital...SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
Catalent & TFF Pharmaceuticals Announce New Inhalation Dry Powder Development & Manufacturing Agreement March 1, 2022
Catalent and TFF Pharmaceuticals, Inc. recently announced their collaboration agreement focused on the generation, testing, and manufacture of dry powder...Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics February 23, 2022
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to….
Allarity Therapeutics & Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib & Stenoparib January 3, 2022
Allarity Therapeutics, Inc. and Oncoheroes Biosciences, Inc. recently announced they have entered into licensing agreements under which Oncoheroes will acquire exclusive, global development rights to Allarity’s therapeutic candidates….
Lantern Pharma & Allarity Therapeutics Enter Into Agreement for Future Clinical Development of Irofulven July 28, 2021
Allarity Therapeutics A/S and Lantern Pharma Inc. recently announced they have entered into an exclusive agreement under which Lantern will reacquire global rights to Irofulven (LP-100) and assume full….
Cytovia Therapeutics Partners Enters Research & Licensing Agreement With Inserm October 14, 2020
Cytovia Therapeutics recently announced it has entered a research and licensing agreement with Inserm to develop NK engager bi-specific antibodies and iPSC CAR NK cell therapy targeting….
TFF Pharmaceuticals Enters into Worldwide Licensing Agreement With UNION Therapeutics August 19, 2020
TFF Pharmaceuticals, Inc. recently announced it has entered into a worldwide exclusive licensing agreement with UNION therapeutics A/S (UNION) for...Relief Therapeutics & NeuroRx Expand Clinical Trial of COVID-19 Drug June 11, 2020
Relief Therapeutics and its US partner, NeuroRx, Inc. recently announced that the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with…
Therapeutic Solutions International Obtains Exclusive License for Patented Clinical Stage Adult Stem Cell July 1, 2019
Therapeutics Solutions International, Inc. recently announced signing of a license agreement providing exclusive rights to a patented adult stem cell...Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner May 23, 2019
Precision Therapeutics Inc. recently announced its Helomics division has been selected as the preferred laboratory to provide laboratory services for...
